0.45Open0.45Pre Close0 Volume699 Open Interest3.00Strike Price0.00Turnover300.10%IV49.40%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.45Extrinsic Value100Contract SizeAmericanOptions Type-0.1457Delta0.0574Gamma11.20Leverage Ratio-0.0180Theta-0.0007Rho-1.63Eff Leverage0.0030Vega
Candel Therapeutics Stock Discussion
5.30+
Now Let's Get That 10.+ Back!
Let's Get 5.+
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Candel Therapeutics announced preclinical results for CAN-3110 in melanoma models, showing potential expansion beyond high-grade glioma treatment. CAN-3110, a first-in-class HSV-1 oncolytic viral immunotherapy, demonstrated potent antitumor activity in both in vitro human cel...
No comment yet